✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Best Longevity Peptides: Epitalon, NAD⁺, SS-31, MOTS-c and the Cellular-Ageing Research Compounds

“Longevity peptide” in the research-literature sense covers compounds with documented effects on cellular-ageing endpoints — telomere length / telomerase activity, mitochondrial function and oxidative phosphorylation efficiency, NAD⁺ pool restoration, autophagy and proteostasis, and sirtuin-pathway activation. The five peptides on the MedsBase catalogue with substantive longevity-research applicability are ranked below, with mechanism class, regulatory status, and the specific research scenario each fits best.

This is the newest and arguably most rapidly-evolving cluster in the peptide research literature — many of the published readouts are from the past 5-10 years, and several compounds (notably SS-31) are in active clinical development.

How to use this hub

• Telomere biology research: Epitalon (the prototype telomerase-activator peptide).
• Mitochondrial function research: SS-31 (cardiolipin-targeted), MOTS-c (mitochondrial-derived AMPK activator).
• Redox / metabolic cofactor research: NAD⁺ (direct cofactor administration).
• Age-related-decline crossover: GHK-Cu (declining plasma levels with age; collagen and tissue-repair endpoints).

1. Epitalon (the prototype longevity peptide)

Mechanism class: Synthetic tetrapeptide (Ala-Glu-Asp-Gly); pineal-axis modulator · CAS: 307297-39-8 · View product · Full research guide

Epitalon is the most-published longevity peptide in the Russian academic-medicine literature. The molecule was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson, who proposed and tested the hypothesis that short peptides derived from pineal-gland tissue could modulate telomerase activity and slow age-related decline. The Khavinson published literature includes multi-year follow-up data in elderly Russian subjects with measurable mortality and morbidity endpoints — a body of work that is methodologically distinct from the Phase 2/3 Western trial literature but is genuine clinical-research data.

Mechanistically, Epitalon has documented effects on telomerase activation (extending telomere length in cultured cell systems), pineal melatonin synthesis (restoring age-related declines), and circadian-rhythm modulation. Western mechanism research is sparser but has confirmed the telomerase-activity effect in in vitro models.

The compound is studied predominantly via subcutaneous administration in research-protocol designs, typically in cyclical patterns (10-20 days of administration followed by a longer rest period) rather than continuous dosing — the cycling pattern is built into the Khavinson published protocols.

Pick for: telomere-biology research; pineal-axis / circadian-research protocols; the reference compound for the Khavinson longevity-research framework.

2. SS-31 / Elamipretide (cardiolipin-targeted mitochondrial peptide)

Mechanism class: Synthetic tetrapeptide; cardiolipin-binding mitochondrial-membrane protector · CAS: 736992-21-5 · Regulatory: FDA orphan-drug designation for primary mitochondrial myopathy · View product · Full research guide

SS-31 (also called Elamipretide or Bendavia) is the longest-developed compound in this cluster — Stealth BioTherapeutics has been advancing the molecule through Phase 2 and Phase 3 trials for nearly a decade, with the most advanced indication being primary mitochondrial myopathy (where FDA orphan-drug designation was granted, marking the molecule has passed Phase 2 safety milestones). Other studied indications include Barth syndrome, age-related macular degeneration (where Phase 2 ReNEW data is published), heart failure with preserved ejection fraction, and Leber’s hereditary optic neuropathy.

Mechanistically, SS-31 binds cardiolipin — the unique phospholipid found in the inner mitochondrial membrane that organises the electron-transport chain complexes for efficient oxidative phosphorylation. Cardiolipin oxidation and loss with ageing is one of the molecular mechanisms underlying age-related mitochondrial decline. SS-31 binding stabilises the cardiolipin pool, supports ETC efficiency, and reduces reactive-oxygen-species leak.

This is the longevity-cluster compound with the most clinical-trial data and the clearest regulatory trajectory. Note: the orphan-drug designation refers to the indication of primary mitochondrial myopathy specifically; the molecule is not FDA-approved for general use.

Pick for: mitochondrial-function research; cardiolipin / ETC research; age-related mitochondrial-decline protocols; the clinical-development-stage longevity compound.

3. NAD⁺ (the central redox cofactor)

Mechanism class: Nicotinamide adenine dinucleotide; central redox cofactor · CAS: 53-84-9 · View product · Full research guide

NAD⁺ is not a peptide in the conventional sense but is included on the MedsBase peptide catalogue and in this longevity hub because age-related NAD⁺ pool decline is one of the most-replicated findings in cellular-ageing research, and direct NAD⁺ restoration is the simplest research intervention against that finding. Falling NAD⁺ levels with age affect every downstream pathway that uses NAD⁺ as a cofactor or substrate — oxidative phosphorylation (ATP production), sirtuin enzymes (SIRT1-7; chromatin remodelling and longevity-pathway regulation), PARPs (DNA-damage repair), and CD38 (the enzyme whose increased activity with age is itself a primary driver of NAD⁺ decline).

Direct NAD⁺ administration in published research uses IV infusion (the highest-bioavailability route) or subcutaneous injection (lower bioavailability but more practical for sustained research protocols). Oral bioavailability is limited because NAD⁺ is degraded in the gut. NAD⁺ precursors (NMN, NR) are an alternative research-intervention path that bypasses the oral-degradation problem; the MedsBase catalogue offers direct NAD⁺.

Pick for: redox / cellular-energetics longevity research; sirtuin-pathway protocols; protocols where the direct-NAD⁺ administration arm is needed alongside NAD⁺-precursor (NMN/NR) comparison arms.

4. MOTS-c (mitochondrial-derived peptide; AMPK activator)

Mechanism class: 16-amino-acid mitochondrial-derived peptide; AMPK activator · CAS: 1627580-64-6 · View product

MOTS-c is the most-studied member of the mitochondrial-derived peptide (MDP) class — short peptides encoded within the mitochondrial genome rather than the nuclear genome. The peptide is encoded within the 12S rRNA gene of mitochondrial DNA and is secreted from mitochondria to act as a hormone-like signalling molecule with metabolic effects in skeletal muscle, adipose tissue, and (relevant for longevity research) in many other tissues showing age-related decline.

Mechanistically, MOTS-c activates AMPK signalling — the master energy-sensor kinase that promotes catabolic energy-producing pathways and suppresses anabolic energy-consuming ones. AMPK activation is one of the most-replicated longevity-intervention mechanisms in animal models, achieved by caloric restriction, metformin, exercise, and a small number of pharmaceutical AMPK agonists. MOTS-c is the only peptide AMPK agonist with substantial published research.

MOTS-c levels decline with age in parallel with mitochondrial dysfunction; restoring MOTS-c levels through exogenous administration is studied as an exercise-mimetic and metabolic-flexibility intervention. The peptide is also studied in the cognitive / neural-energetics literature (see the nootropic peptides hub for the cognitive applications).

Pick for: AMPK-signalling longevity research; mitochondrial-derived peptide research; exercise-mimetic protocols; age-related metabolic-flexibility research.

5. GHK-Cu (age-related-decline endpoints with longevity-research crossover)

Mechanism class: Copper-chelated tripeptide; multi-pathway · View product · Full research guide

GHK-Cu lives primarily in the cosmetic peptides hub, but the molecule has substantial longevity-research applicability worth surfacing here. The native GHK tripeptide is naturally present in human plasma at concentrations that decline with age — the published age-related-decline curve shows GHK plasma levels falling roughly 60% between age 20 and age 60. Restoring GHK plasma levels through exogenous GHK-Cu administration is studied as a research intervention against multiple age-related-decline endpoints: collagen synthesis decline, extracellular matrix deterioration, hair-follicle stem-cell senescence, and impaired wound healing.

The longevity-research framing positions GHK-Cu alongside Epitalon and SS-31 as a “replacing what age depletes” intervention — distinct from the AMPK / sirtuin pathway modulators (NAD⁺, MOTS-c) which work upstream of multiple age-related-decline endpoints.

Pick for: age-related-decline endpoint research; collagen / matrix / tissue-repair longevity protocols; the “replacing depleted endogenous compound” longevity-intervention framework.

Comparison table

The longevity-peptide mechanism map

One useful frame for thinking about the cluster: the five compounds operate on five distinct “axes” of cellular ageing, and the strongest research-protocol designs combine compounds from non-overlapping axes rather than stacking compounds within the same axis. The five axes:

• Telomere biology: Epitalon. Endpoint: telomere length, telomerase activity, cellular replicative capacity.
• Mitochondrial membrane integrity: SS-31. Endpoint: cardiolipin levels, ETC efficiency, ROS leak.
• Mitochondrial signalling: MOTS-c. Endpoint: AMPK activation, metabolic flexibility, oxidative capacity.
• Redox cofactor pools: NAD⁺. Endpoint: NAD⁺/NADH ratio, sirtuin activity, PARP activity.
• Tissue-level age-related decline: GHK-Cu. Endpoint: collagen synthesis, matrix remodelling, follicle stem-cell function.

The mechanistic logic is that each axis can decline somewhat independently — and that an effective longevity-intervention research design covers as many axes as the protocol budget allows, rather than over-stacking a single mechanism.

Frequently asked research questions

What is the Khavinson published literature and why is it different from Western trial data?

Vladimir Khavinson is a Russian gerontologist who developed Epitalon and a series of related short peptides (“Khavinson peptides”) at the St. Petersburg Institute of Bioregulation and Gerontology. His published literature includes multi-year follow-up clinical-research data in elderly Russian subjects with mortality and morbidity endpoints. The methodology is distinct from Phase 2/3 Western randomised-trial designs — the studies are open-label and population-comparison rather than placebo-controlled — but the data is genuine clinical-research data and a substantial body of work. The Russian academic-medicine literature is in many places thinner than Western publication mainstream; in longevity peptides specifically, the Khavinson body of work is the most-cited.

What does FDA orphan-drug designation actually mean for SS-31 / Elamipretide?

It means the FDA recognises the molecule is in development for a specific rare disease (primary mitochondrial myopathy, in this case) and has granted the developer (Stealth BioTherapeutics) a set of regulatory benefits — tax credits, fee waivers, and a 7-year market exclusivity period upon approval. The designation also signals the molecule has passed Phase 2 safety milestones for that indication. Critical detail: orphan-drug designation is not the same as FDA approval. The compound is still in development; it is not approved for general use in any indication.

Is NAD⁺ better than its precursors NMN and NR?

Different research questions. Direct NAD⁺ administration delivers the cofactor to the systemic circulation but bypasses cellular uptake mechanisms — most cells cannot import intact NAD⁺; they import the precursors (NMN, NR, nicotinamide) and convert them intracellularly via the salvage pathway. NMN and NR are the precursors most commonly used in published research because the intracellular conversion is well-characterised and oral bioavailability is documented. Direct NAD⁺ via IV or SC delivers a temporary plasma spike that supports endothelial / vascular endpoints and may be useful for that specific research scenario. Most longevity-research protocols use NMN or NR; direct NAD⁺ sits as a comparator option.

What is the relationship between MOTS-c and exercise?

Exercise raises endogenous MOTS-c levels — published research shows exercise-induced MOTS-c elevation correlates with improved metabolic flexibility, insulin sensitivity, and AMPK activation. Exogenous MOTS-c administration produces a similar set of downstream effects in research models, which is why the compound is framed as an “exercise-mimetic” research tool. The cleanest research scenarios use MOTS-c in models where exercise is not available (immobilised research subjects, age-related sarcopenia models, in-vitro cellular systems).

Can Epitalon really activate telomerase?

The mechanism is documented in cultured-cell systems and animal models. Epitalon administration to telomerase-negative cell lines (somatic fibroblasts that normally have no telomerase activity) induces measurable telomerase activity and modest telomere elongation. In animal models, Epitalon-treated animals show longer maximum lifespans than controls in several published rodent studies. Whether the cell-culture and animal-model effects translate to meaningful human-clinical telomere extension is genuinely uncertain — the Khavinson Russian literature suggests yes, but the methodological standards make direct translation to Western framework comparison difficult. For research purposes, the molecule has documented telomerase-modulating activity; for clinical-extrapolation purposes, the evidence base is narrower than mitochondrial or cofactor longevity-research compounds.

Why is GHK-Cu on a longevity-peptide list when its primary applications are cosmetic?

Two reasons. First, the molecule satisfies the “replacing what age depletes” criterion explicitly — GHK plasma levels fall ~60% between age 20 and age 60, and exogenous administration restores those levels. Second, the cosmetic endpoints (collagen synthesis, matrix remodelling, follicle stem-cell activation) are longevity endpoints; the visible cosmetic effects are downstream of the same age-related cellular processes that longevity research aims to address. The distinction between “cosmetic peptide” and “longevity peptide” is largely categorical rather than mechanistic — both research literatures study the same molecule from different framings.

What is the longest-running clinical-development longevity peptide?

SS-31 (Elamipretide), with Stealth BioTherapeutics having advanced the molecule through Phase 2 and Phase 3 trials for nearly a decade across multiple indications. The compound is the only longevity-cluster peptide with substantial Western pharma-development data. The MMPOWER-3 Phase 3 trial for primary mitochondrial myopathy was the highest-profile readout; the AGEMAP cardiovascular trials and the ReNEW age-related macular degeneration trial are also in the published record.

What is the typical storage protocol for longevity peptides?

Same as the rest of the catalogue: lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw the reconstituted solution. NAD⁺ specifically requires careful protection from oxidation in the reconstituted form (NAD⁺ readily oxidises to NADH in solution and the redox ratio matters for downstream pharmacology).

Bottom line

The longevity-peptide cluster is the newest and most-rapidly-evolving research cluster on the MedsBase catalogue. Epitalon is the Khavinson reference compound and the prototype telomere-biology peptide; SS-31 is the most clinically advanced (FDA orphan-drug designation) and the cardiolipin / mitochondrial-membrane reference; NAD⁺ is the direct-cofactor option in the redox-restoration framework; MOTS-c is the AMPK-signalling and exercise-mimetic compound; GHK-Cu is the “replacing what age depletes” tissue-repair option. The most-published research-protocol designs combine compounds from non-overlapping mechanism axes rather than stacking within a single axis — for example, SS-31 (mitochondrial membrane) + MOTS-c (mitochondrial signalling) + Epitalon (telomere) covers three distinct ageing pathways in a single design.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.